Clinical Trial Update: Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 [Phase 3]

View source ↗

Summary

This Phase 3 trial by NRG Oncology is evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves outcomes f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: NRG Oncology | Conditions: Breast Cancer | Phase 3 | Status: RECRUITING